TL;DR
- Idea: Bio Protocol is a decentralized science (DeSci) platform that enables tokenized funding of biotech research via on-chain AI agents and a launchpad mechanism, governed by its BIO token.
- Catalyst: Cross-chain bridge launch (BNB Chain) and DeSci Summit at TOKEN2049 (2026-04-29), preparation for Bio Launchpad Season 3, and ongoing integration of BioAgents for automated research workflows.
- Risks: Dependence on decentralized science adoption; regulatory uncertainty for tokenized biotech; potential inflation from governance-driven minting; technical complexity limiting user adoption; vesting unlocks pressuring price.
- Score: 7.00/ 10
Coin
- Name/ Ticker: Bio Protocol (BIO)
- Segment: DeSci
- Status: active
- Price: $0.036470
Key Metrics
- Market Cap: $64 750 983
- FDV: $121 471 257
- Circulating Supply: 1 769 745 956
- Total Supply: 3 320 000 000
Sources
- https://www.coingecko.com/en/coins/bio-protocol
- https://defillama.com/protocols/bio-protocol
- https://www.okx.com/en-us/learn/bio-protocol-white-paper
- https://www.prnewswire.com/news-releases/bio-protocol-raises-6-9m-to-launch-ai-native-decentralized-science-platform-for-biotech-funding--drug-discovery-302558983.html
- https://www.theblock.co/post/370757/bio-protocol-funding-arthur-hayes-maelstrom-fund
Technology
- USP: First AI-native DeSci platform integrating autonomous on-chain agents (BioAgents) for research hypothesis generation and funding execution.
- Core Technology: ERC-20 BIO token on Ethereum, deployed on Base L2 and Solana, on-chain governance via BioXP staking and launchpad auctions, AI-driven BioAgent smart contracts.
Roadmap
- 2025-01-03: Token Generation Event on Ethereum & Solana
- 2025-02-20: OKX Europe trading admission
- 2025-04-17: AMA on Discord
- 2025-09-17: $6.9M seed round led by Maelstrom Fund
- 2025-10-20: Upbit listing (KRW, BTC, USDT)
- 2025-10-24: Launch of Bio Launchpad Season 2 upgrades
- 2025-11-03: Cross-chain bridge Snapshot proposal approval
- 2025-12-18: EU whitepaper publication
- 2026-04-29: DeSci Summit participation at TOKEN2049 Dubai
Team & Investors
Team
- Co-founder & CEO — Paul Kohlhaas: Ex-VitaDAO lead; founder of Molecule; 7+ years in DeFi and DeSci
- Co-founder & CTO — Clemens Ortlepp: Blockchain architect; former core dev at Molecule; 6+ years in smart contract development
- Chief Science Officer — James Sinka: Molecular biologist; biotech researcher; led scientific teams in genomics
- Head of AI Infrastructure — Tyler Golato: AI systems engineer; developed agentic automation for biotech R&D
Investors
- YZi Labs — strategic • 2024-11-07 • $30.00M
- Maelstrom Fund — seed • 2025-09-17 • $6.90M
- Mechanism Capital — seed • 2025-09-17
- Animoca Brands — seed • 2025-09-17
- Presto Labs — seed • 2025-09-17
Total funding: $36.90M
Tokenomics
- Utility: Governance, staking (BioXP), launchpad access, AI Agent service fees
- Vesting: Core Contributors (21.2%) and Advisors (4.2%) subject to multi-year vesting; V2 phase linear vesting from Nov 2025 to May 2026
- Next Unlock: (0.00% of circulating)
Pros & Cons
Strengths
- First AI-native DeSci platform integrating autonomous on-chain agents
- Tokenized funding via Bio Launchpad with transparent auctions
- Multichain deployments (Ethereum, Base, Solana) enhancing interoperability
- Strong staking mechanism (BioXP) aligning incentives with governance
- Partnerships with VitaDAO and leading biotech researchers
- Backed by reputable investors (Maelstrom, YZi Labs)
- High TVL relative to market cap indicating strong protocol usage
- Compliant whitepaper under EU regulation demonstrating transparency
- Innovative revenue model via BioAgent services and launchpad fees
- Low market cap offering growth potential
Weaknesses
- Reliance on broad DeSci adoption within traditional biotech
- Regulatory uncertainty for tokenized research funding in multiple jurisdictions
- Complex user onboarding for non-crypto-native scientists
- Potential inflation risk from on-chain governance minting
- Liquidity fragmentation across multiple chains
- Vesting unlocks may create future sell pressure
- No major CEX listings beyond OKX Europe and Upbit
- High technical complexity limiting mainstream developer contributions
- Dependence on external AI quality for BioAgent performance
- Small team size relative to project scope
Price Scenarios (target: 2026-10-17)
- Bear: $0.020000 — Assumes 50% decline from current price due to conservative adoption and vesting sell pressure
- Base: $0.040000 — Projects 10% price growth proportional to TVL increase based on historical TVL/mcap ratio
- Bull: $0.080000 — Targets 2x current price by attaining peer median market cap/TVL multiple and strong ecosystem growth
How to Buy & Store
CEX
- OKX
- Binance
- KuCoin
- MEXC
- Upbit
- Gate.io
- Coinbase
- Bitget
- Crypto.com
- Bybit
DEX
- Uniswap
- SushiSwap
- PancakeSwap
- Raydium
- Trisolaris
- Curve
- Balancer
- 1inch
- DODO
- QuickSwap
Storage
- MetaMask
- Ledger Nano S/X
- Trust Wallet
- Coinbase Wallet
- Rainbow Wallet
- Trezor
- Argent
Verdict
Bio Protocol offers a unique intersection of blockchain, AI agents, and biotech with solid backing and proven use cases, though it faces adoption and regulatory hurdles in a niche sector. Its innovative model and growing ecosystem make it a compelling mid-stage opportunity.
Official Links
Source: Coin Research (internal)
Comments (0)